Skip to content
MedsAcross

Fixed-dose combination

Bupivacaine and Epinephrine

Also known as bupivacaine hydrochloride, bupivacaine hydrochloride anhydrous, epinephrine bitartrate
Available on request
Presentations
22
Brands
5
Manufacturers
3
Available from stock
0

Bupivacaine and Epinephrine is a fixed-dose combination of an amide local anesthetic, a catecholamine and an alpha-adrenergic agonist. It is available as injection for perineural, epidural and intracaudal use. MedsAcross supplies Bupivacaine and Epinephrine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Key facts

Pharmacological class
Alpha-Adrenergic Agonist, Amide Local Anesthetic, Beta-Adrenergic Agonist, Catecholamine, Adrenergic alpha-Agonists, Adrenergic beta-Agonists, Local Anesthesia
US FDA first approval
3 October 1972
EU status
Not recorded
Orphan designation
Not recorded
WHO essential medicine
Not recorded
India (CDSCO)
Not yet confirmed against CDSCO approval lists
Routes
Perineural, Epidural, Intracaudal, Infiltration, Submucosal, Retrobulbar
Dosage forms
Injection
Fixed-dose combination of
Bupivacaine, Epinephrine
Identifiers
RxCUI 107606Q48566674

Clinical information

From the regulator-approved product information. Each section names its source.

Uses

MARCAINE / MARCAINE WITH EPINEPHRINE is indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Specific concentrations and presentations of MARCAINE / MARCAINE WITH EPINEPHRINE are recommended for each type of block indicated to produce local or regional anesthesia or analgesia. MARCAINE contains bupivacaine, an amide local anesthetic, and MARCAINE WITH EPINEPHRINE is a combination of bupivacaine, an amide local anesthetic, and epinephrine, an alpha and beta-adrenergic agonist. For each type of block indicated to produce local or regional anesthesia or analgesia, specific concentrations and presentations are recommended.

Source: US FDA prescribing information

How it works

Bupivacaine blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction velocity of affected nerve fibers. Clinically, the order of loss of nerve function is as follows: pain, temperature, touch, proprioception, and skeletal muscle tone. Epinephrine is a vasoconstrictor added to bupivacaine to slow absorption into the general circulation and thus prolong maintenance of an active tissue concentration.

Source: US FDA prescribing information

Dosing overview

• Not for intrathecal use. • Avoid use of solutions containing antimicrobial preservatives (i.e., multiple-dose vials) for epidural or caudal anesthesia. • Three mL of MARCAINE WITH EPINEPHRINE without antimicrobial preservative (0.5% bupivacaine with 1:200,000 epinephrine ) is recommended for use as a test dose prior to caudal and lumbar epidural blocks when clinical conditions permit. • See full prescribing information for: - Recommended concentrations and dosages of MARCAINE / MARCAINE WITH EPINEPHRINE according to type of block. - Additional dosage and administration information pertaining to use in epidural anesthesia, test dose for caudal and lumbar epidural blocks, use in dentistry, and use in ophthalmic surgery.

Source: US FDA prescribing information

Contraindications

MARCAINE / MARCAINE WITH EPINEPHRINE is contraindicated in: • obstetrical paracervical block anesthesia. Its use in this technique has resulted in fetal bradycardia and death. • intravenous regional anesthesia (Bier Block). • patients with a known hypersensitivity to bupivacaine or to any local anesthetic agent of the amide-type or to other components of MARCAINE / MARCAINE WITH EPINEPHRINE. • Obstetrical paracervical block anesthesia. Its use in this technique has resulted in fetal bradycardia and death. • Intravenous regional anesthesia (Bier Block).

Source: US FDA prescribing information

Warnings and precautions

Boxed warning (risk of cardiac arrest with use of marcaine in obstetrical anesthesia): There have been reports of cardiac arrest with difficult resuscitation or death during use of MARCAINE for epidural anesthesia in obstetrical patients. In most cases, this has followed use of the 0.75% (7.5 mg/mL) concentration. Resuscitation has been difficult or impossible despite apparently adequate preparation and appropriate management. • Dose-Related Toxicity: Monitor cardiovascular and respiratory vital signs and patient's state of consciousness after injection of MARCAINE / MARCAINE WITH EPINEPHRINE. • Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use. See full prescribing information for more detail on managing these risks.

Source: US FDA prescribing information

Side effects

The following clinically significant adverse reactions have been reported and described in the Warnings and Precautions section of the labeling: • Cardiac Arrest in Obstetrical Anesthesia • Dose-Related Toxicity • Methemoglobinemia • Chondrolysis with Intra-Articular Infusion • Severe, Persistent Hypertension, Cerebrovascular Accidents, and Bradycardia Due to Drug Interactions • Cardiac Arrest with Intravenous Regional Anesthesia Use • Allergic-Type Reactions • Systemic Toxicities with Unintended Intravascular or Intrathecal Injection • Respiratory Arrest Following Retrobulbar Block The following adverse reactions from voluntary reports or clinical studies have been reported with bupivacaine or bupivacaine and epinephrine.

Source: US FDA prescribing information

Interactions

• Local Anesthetics: The toxic effects of local anesthetics are additive. Monitor for neurologic and cardiovascular effects when additional local anesthetics are administered. • Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: Administration of MARCAINE WITH EPINEPHRINE to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension. Concurrent use of these agents should generally be avoided. • Ergot-Type Oxytocic Drugs: Concurrent administration of MARCAINE WITH EPINEPHRINE and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. • Nonselective Beta-Adrenergic Antagonists: Administration of MARCAINE WITH EPINEPHRINE (containing a vasoconstrictor) in patients receiving nonselective beta-adrenergic antagonists may cause severe hypertension and bradycardia.

Source: US FDA prescribing information

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

All presentations

22 presentations of Bupivacaine and Epinephrine, sorted by availability.

MedicineActive ingredientManufacturerRegisterAvailability
Bupivacaine and Epinephrine 125 mg/0.25 mg per 50 mL injectionInfiltration, perineuralGeneric nameBupivacaine and Epinephrine—US FDAAvailable on request
Bupivacaine and Epinephrine 250 mg/0.25 mg per 50 mL injectionPerineuralGeneric nameBupivacaine and Epinephrine—US FDAAvailable on request
Marcaine with Epinephrine 75 mg/0.273 mg per 30 mL injectionEpidural, infiltration, intracaudal, perineuralBupivacaine and EpinephrineHospiraUS FDAAvailable on request
Sensorcaine 250 mg/0.25 mg per 50 mL injectionPerineuralBupivacaine and EpinephrineFresenius KabiUS FDAAvailable on request
Marcaine with Epinephrine 125 mg/0.455 mg per 50 mL injectionInfiltration, perineuralBupivacaine and EpinephrineHospiraUS FDAAvailable on request
Marcaine with Epinephrine 150 mg/0.273 mg per 30 mL injectionEpidural, intracaudal, perineuralBupivacaine and EpinephrineHospiraUS FDAAvailable on request
Marcaine with Epinephrine 25 mg/0.091 mg per 10 mL injectionEpidural, infiltration, intracaudal, perineuralBupivacaine and EpinephrineHospiraUS FDAAvailable on request
Marcaine with Epinephrine 250 mg/0.455 mg per 50 mL injectionPerineuralBupivacaine and EpinephrineHospiraUS FDAAvailable on request
Marcaine with Epinephrine 50 mg/0.091 mg per 10 mL injectionEpidural, intracaudal, perineuralBupivacaine and EpinephrineHospiraUS FDAAvailable on request
Sensorcaine MPF 150 mg/0.15 mg per 30 mL injectionEpidural, intracaudal, perineuralBupivacaine and EpinephrineFresenius KabiUS FDAAvailable on request
Sensorcaine MPF 75 mg/0.15 mg per 30 mL injectionEpidural, infiltration, intracaudal, perineuralBupivacaine and EpinephrineFresenius KabiUS FDAAvailable on request
Bupivacaine and Epinephrine 150 mg/150 mcg per 30 mL injectionEpidural, intracaudal, perineuralGeneric nameBupivacaine and Epinephrine—US FDAAvailable on request
Bupivacaine and Epinephrine 25 mg/50 mcg per 10 mL injectionEpidural, infiltration, intracaudal, perineuralGeneric nameBupivacaine and Epinephrine—US FDAAvailable on request
Bupivacaine and Epinephrine 50 mg/50 mcg per 10 mL injectionEpidural, intracaudal, perineuralGeneric nameBupivacaine and Epinephrine—US FDAAvailable on request
Bupivacaine and Epinephrine 75 mg/150 mcg per 30 mL injectionEpidural, infiltration, intracaudal, perineuralGeneric nameBupivacaine and Epinephrine—US FDAAvailable on request
Marcaine 9 mg/0.009 mg per 1.8 mL injectionSubmucosalBupivacaine and EpinephrineSeptodontUS FDAAvailable on request
Sensorcaine 125 mg/0.25 mg per 50 mL injectionInfiltration, perineuralBupivacaine and EpinephrineFresenius KabiUS FDAAvailable on request
Sensorcaine MPF 150 mg/0.15 mg per 30 mL injectionEpidural, infiltration, intracaudal, perineuralBupivacaine and EpinephrineFresenius KabiUS FDAAvailable on request
Sensorcaine MPF 225 mg/0.15 mg per 30 mL injectionEpidural, retrobulbarBupivacaine and EpinephrineFresenius KabiUS FDAAvailable on request
Sensorcaine MPF 25 mg/0.05 mg per 10 mL injectionEpidural, infiltration, intracaudal, perineuralBupivacaine and EpinephrineFresenius KabiUS FDAAvailable on request
Sensorcaine MPF 50 mg/0.05 mg per 10 mL injectionEpidural, intracaudal, perineuralBupivacaine and EpinephrineFresenius KabiUS FDAAvailable on request
Vivacaine 9 mg/0.009 mg per 1.8 mL injectionSubmucosalBupivacaine and EpinephrineSeptodontUS FDAAvailable on request

Brands by market

5 brand names across 1 markets.

Brand names by country

Manufacturers

Regulatory status

Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.

RegisterStatusSource
US FDAFirst approved 3 October 1972Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Questions and answers

Is Bupivacaine and Epinephrine available for export from India?

Yes, on request. MedsAcross lists 22 presentations of Bupivacaine and Epinephrine and sources them for licensed hospitals, importers and physicians against valid import documents.

What brand names does Bupivacaine and Epinephrine have?

The catalogue lists 5 brand names for Bupivacaine and Epinephrine, including Marcaine, Marcaine with Epinephrine, Sensorcaine, Sensorcaine MPF, Vivacaine.

Is Bupivacaine and Epinephrine approved by the US FDA?

Yes. The US FDA first approved Bupivacaine and Epinephrine on 3 October 1972, according to Drugs@FDA.

Does Bupivacaine and Epinephrine need cold chain shipping?

No listed presentation of Bupivacaine and Epinephrine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.

References

  1. Marcaine prescribing information (Hospira). U.S. National Library of Medicine, DailyMed. Retrieved 23 October 2026

Request Bupivacaine and Epinephrine for export supply

Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.